Amit Munshi - Net Worth and Insider Trading
Amit Munshi Net Worth
The estimated net worth of Amit Munshi is at least $8 Million dollars as of 2024-11-05. Amit Munshi is the President and CEO of Arena Pharmaceuticals Inc and owns about 39,550 shares of Arena Pharmaceuticals Inc (ARNA) stock worth over $4 Million. Amit Munshi is the Director of Zura Bio Ltd and owns about 777,384 shares of Zura Bio Ltd (ZURA) stock worth over $3 Million. Amit Munshi is also the Director of Inhibikase Therapeutics Inc and owns about 365,000 shares of Inhibikase Therapeutics Inc (IKT) stock worth over $967,250. Details can be seen in Amit Munshi's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Amit Munshi has not made any transactions after 2024-10-21 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Amit Munshi
Amit Munshi Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Amit Munshi owns 6 companies in total, including Arena Pharmaceuticals Inc (ARNA) , Pulmatrix Inc (PULM) , and EPIRUS Biopharmaceuticals Inc (EPRSQ) among others .
Click here to see the complete history of Amit Munshi’s form 4 insider trades.
Insider Ownership Summary of Amit Munshi
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ARNA | Arena Pharmaceuticals Inc | 2021-08-16 | director & President and CEO |
| PULM | Pulmatrix Inc | 2017-06-13 | director |
| EPRSQ | EPIRUS Biopharmaceuticals Inc | 2016-02-27 | director & Chief Executive Officer |
 | | 2020-10-28 | director |
| | 2021-06-29 | director |
| | 2024-04-22 | director |
Amit Munshi Latest Holdings Summary
Amit Munshi currently owns a total of 3 stocks. Among these stocks, Amit Munshi owns 39,550 shares of Arena Pharmaceuticals Inc (ARNA) as of August 16, 2021, with a value of $4 Million and a weighting of 48.44%. Amit Munshi owns 777,384 shares of Zura Bio Ltd (ZURA) as of April 22, 2024, with a value of $3 Million and a weighting of 39.71%. Amit Munshi also owns 365,000 shares of Inhibikase Therapeutics Inc (IKT) as of October 21, 2024, with a value of $967,250 and a weighting of 11.85%.
Latest Holdings of Amit Munshi
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ARNA | Arena Pharmaceuticals Inc | 2021-08-16 | 39,550 | 99.99 | 3,954,605 |
| ZURA | Zura Bio Ltd | 2024-04-22 | 777,384 | 4.17 | 3,241,691 |
| IKT | Inhibikase Therapeutics Inc | 2024-10-21 | 365,000 | 2.65 | 967,250 |
Holding Weightings of Amit Munshi
Amit Munshi Form 4 Trading Tracker
According to the SEC Form 4 filings, Amit Munshi has made a total of 11 transactions in Arena Pharmaceuticals Inc (ARNA) over the past 5 years, including 3 buys and 8 sells. The most-recent trade in Arena Pharmaceuticals Inc is the acquisition of 1,000 shares on August 16, 2021, which cost Amit Munshi around $48,190.
According to the SEC Form 4 filings, Amit Munshi has made a total of 2 transactions in Zura Bio Ltd (ZURA) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Zura Bio Ltd is the acquisition of 159,744 shares on April 22, 2024, which cost Amit Munshi around $499,999.
According to the SEC Form 4 filings, Amit Munshi has made a total of 1 transactions in Inhibikase Therapeutics Inc (IKT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Inhibikase Therapeutics Inc is the acquisition of 365,000 shares on October 21, 2024, which cost Amit Munshi around $500,050.
Insider Trading History of Amit Munshi
- 1
Amit Munshi Trading Performance
GuruFocus tracks the stock performance after each of Amit Munshi's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Amit Munshi is 32.67%. GuruFocus also compares Amit Munshi's trading performance to market benchmark return within the same time period. The performance of stocks bought by Amit Munshi within 3 months outperforms 6 times out of 7 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Amit Munshi's insider trading performs compared to the benchmark.
Performance of Amit Munshi
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 21.45 | | | | | |
| Relative Return to S&P 500(%) | 19.56 | | | | | |
Amit Munshi Ownership Network
Ownership Network List of Amit Munshi
Ownership Network Relation of Amit Munshi
Amit Munshi Owned Company Details
What does Arena Pharmaceuticals Inc do?
Who are the key executives at Arena Pharmaceuticals Inc?
Amit Munshi is the director & President and CEO of Arena Pharmaceuticals Inc. Other key executives at Arena Pharmaceuticals Inc include EVP & Chief Commercial Officer Robert Lisicki , Executive VP and CBO Vincent Aurentz , and EVP & Head of R&D & and CMO Christopher Cabell .
Arena Pharmaceuticals Inc (ARNA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Arena Pharmaceuticals Inc (ARNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arena Pharmaceuticals Inc (ARNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Arena Pharmaceuticals Inc (ARNA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arena Pharmaceuticals Inc Insider Transactions
Amit Munshi Mailing Address
Above is the net worth, insider trading, and ownership report for Amit Munshi. You might contact Amit Munshi via mailing address: C/o Epirus Biopharmaceuticals, Inc., 699 Boylston Street, 8th Floor, Boston Ma 02116.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
